DeCamp Lisa Ross, Byerley Julie S, Doshi Nipa, Steiner Michael J
Pediatric Education Office, Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine, Campus Box 7593, Chapel Hill, NC 27599, USA.
Arch Pediatr Adolesc Med. 2008 Sep;162(9):858-65. doi: 10.1001/archpedi.162.9.858.
To perform a systematic review and meta-analysis to determine whether taking antiemetic drugs reduces vomiting and decreases the need for further intervention in children with gastroenteritis without causing significant adverse effects.
Computerized databases, reference lists, and expert recommendations.
Prospective controlled trials evaluating medication use in children with vomiting from gastroenteritis.
Antiemetic drug therapy.
Emesis cessation, use of intravenous fluid for rehydration, hospital admission, return to care, and medication adverse effects.
The 11 articles that met the inclusion criteria evaluated various antiemetic agents: ondansetron (n = 6), domperidone (n = 2), trimethobenzamide (n = 2), pyrilamine-pentobarbital (n = 2), metoclopramide (n = 2), dexamethasone (n = 1), and promethazine (n = 1). Meta-analysis of 6 randomized, double-masked, placebo-controlled trials of ondansetron demonstrated decreased risk of further vomiting (5 studies; relative risk [RR], 0.45; 95% confidence interval [CI], 0.33-0.62; number needed to treat [NNT] = 5), reduced need for intravenous fluid (4 studies; RR, 0.41; 95% CI, 0.28-0.62; NNT = 5), and decreased risk of immediate hospital admission (5 studies; RR, 0.52; 95% CI, 0.27-0.95; NNT = 14). Diarrheal episodes increased in ondansetron-treated patients in 3 studies. Ondansetron use did not significantly affect return to care (5 studies; RR, 1.34; 95% CI, 0.77-2.35).
Ondansetron therapy decreases the risk of persistent vomiting, the use of intravenous fluid, and hospital admissions in children with vomiting due to gastroenteritis. Future treatment guidelines should incorporate ondansetron therapy for select children with gastroenteritis.
进行一项系统评价和荟萃分析,以确定使用止吐药物是否能减少呕吐,并降低对患有肠胃炎儿童进行进一步干预的必要性,同时不会引起显著的不良反应。
计算机化数据库、参考文献列表和专家建议。
评估肠胃炎呕吐儿童用药情况的前瞻性对照试验。
止吐药物治疗。
呕吐停止、使用静脉补液进行补液、住院、恢复护理以及药物不良反应。
符合纳入标准的11篇文章评估了多种止吐药物:昂丹司琼(n = 6)、多潘立酮(n = 2)、曲美苄胺(n = 2)、吡苄明 - 戊巴比妥(n = 2)、甲氧氯普胺(n = 2)、地塞米松(n = 1)和异丙嗪(n = 1)。对6项关于昂丹司琼的随机、双盲、安慰剂对照试验进行的荟萃分析表明,进一步呕吐的风险降低(5项研究;相对风险[RR],0.45;95%置信区间[CI],0.33 - 0.62;治疗所需人数[NNT] = 5),静脉补液的需求减少(4项研究;RR,0.41;95% CI,0.28 - 0.62;NNT = 5),即刻住院风险降低(5项研究;RR,0.52;95% CI,0.27 - 0.95;NNT = 14)。在3项研究中,接受昂丹司琼治疗的患者腹泻发作增加。使用昂丹司琼对恢复护理没有显著影响(5项研究;RR,1.34;95% CI,0.77 - 2.35)。
昂丹司琼治疗可降低肠胃炎呕吐儿童持续性呕吐、静脉补液使用和住院的风险。未来的治疗指南应将昂丹司琼治疗纳入部分肠胃炎儿童的治疗方案中。